Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rx Reimportation Push Resumes: Gutknecht Sees Open Borders As Inevitable

Executive Summary

Personal importation of prescription drugs will inevitably lead to reimportation at the wholesale level, Rep. Gutknecht (R-Minn.) suggested at a Washington, D.C., press conference Jan. 31.

You may also be interested in...



Rx Import Law Could Divert FDA Inspectors From Food Safety, HHS Suggests

Proposals to open the Canadian border for pharmaceutical imports could potentially draw FDA inspectors away from food safety and other priorities, HHS Secretary Tommy Thompson told a Feb. 14 Senate Budget Committee hearing

Rx Import Law Could Divert FDA Inspectors From Food Safety, HHS Suggests

Proposals to open the Canadian border for pharmaceutical imports could potentially draw FDA inspectors away from food safety and other priorities, HHS Secretary Tommy Thompson told a Feb. 14 Senate Budget Committee hearing

Pharmacia VP Friedman Is Among PhRMA Favorites For FDA Commissioner

Pharmacia Senior VP Michael Friedman's recent letter to the New England Journal of Medicine regarding the use of Cytotec (misoprostol) in pregnant women should help continue his candidacy to return to FDA as commissioner.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS037311

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel